LetterLetter
Dr. Kitajima et al reply
Takamasa Kitajima, Atsushi Funauchi, Toshiki Nakajima, Satoshi Marumo, Yoshitaka Imura and Motonari Fukui
The Journal of Rheumatology October 2022, jrheum.220777; DOI: https://doi.org/10.3899/jrheum.220777
Takamasa Kitajima
Respiratory Disease Center, Kitano Hospital, Tazuke Kofukai Medical Research Institute; Department of Clinical Immunology and Rheumatology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. T. Kitajima, Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan. Email: m-kitajima@kitano- hp.or.jp.
Atsushi Funauchi
Respiratory Disease Center, Kitano Hospital, Tazuke Kofukai Medical Research Institute; Department of Clinical Immunology and Rheumatology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. T. Kitajima, Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan. Email: m-kitajima@kitano- hp.or.jp.
Toshiki Nakajima
Respiratory Disease Center, Kitano Hospital, Tazuke Kofukai Medical Research Institute; Department of Clinical Immunology and Rheumatology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. T. Kitajima, Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan. Email: m-kitajima@kitano- hp.or.jp.
Satoshi Marumo
Respiratory Disease Center, Kitano Hospital, Tazuke Kofukai Medical Research Institute; Department of Clinical Immunology and Rheumatology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. T. Kitajima, Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan. Email: m-kitajima@kitano- hp.or.jp.
Yoshitaka Imura
Respiratory Disease Center, Kitano Hospital, Tazuke Kofukai Medical Research Institute; Department of Clinical Immunology and Rheumatology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. T. Kitajima, Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan. Email: m-kitajima@kitano- hp.or.jp.
Motonari Fukui
Respiratory Disease Center, Kitano Hospital, Tazuke Kofukai Medical Research Institute; Department of Clinical Immunology and Rheumatology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. T. Kitajima, Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan. Email: m-kitajima@kitano- hp.or.jp.
Abstract
We thank Mutoh et al1 for their interest in our study on antimelanoma differentiation-associated gene 5 antibody–positive interstitial lung disease (anti-MDA5-ILD) after vaccination with coronavirus disease 2019 (COVID-19) mRNA vaccines2 and for sharing their clinical experience. Mutoh et al1 reported a case of anti-MDA5-ILD that developed 8 weeks after COVID-19 mRNA vaccination in Japan.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Dr. Kitajima et al reply
Takamasa Kitajima, Atsushi Funauchi, Toshiki Nakajima, Satoshi Marumo, Yoshitaka Imura, Motonari Fukui
The Journal of Rheumatology Oct 2022, jrheum.220777; DOI: 10.3899/jrheum.220777